scholarly journals Treatment of Congenital Hyperinsulinism with Lanreotide Acetate (Somatuline Autogel)

2011 ◽  
Vol 96 (8) ◽  
pp. 2312-2317 ◽  
Author(s):  
Dalit Modan-Moses ◽  
Ilana Koren ◽  
Kineret Mazor-Aronovitch ◽  
Orit Pinhas-Hamiel ◽  
Heddy Landau
Keyword(s):  
Insulin Pump ◽  
Glucose Monitoring ◽  
Normal Weight ◽  
Somatostatin Analog ◽  
Good Growth ◽  
Congenital Hyperinsulinism ◽  
Pump Therapy ◽  
Monthly Injection ◽  
Normal Weight Gain ◽  
Long Acting

Abstract Context: Congenital hyperinsulinism (CH) may be treated conservatively in many children with octreotide given by multiple sc injections or via an insulin pump. Objective: We describe two children treated with a once-monthly injection of a long-acting somatostatin analog. Patients and Methods: Both patients presented with hypoglycemia 30 min after birth and were subsequently diagnosed with CH. Patients were initially treated with diazoxide, hydrochlorothiazide, frequent feedings, and octreotide via an insulin pump. With this therapy, they were normoglycemic with a good growth rate, normal weight gain, and excellent neurodevelopment. Treatment with the long-acting somatostatin analog lanreotide acetate (Somatuline Autogel), administered by deep sc injection of 30 mg once a month, was started at the ages of 4½ and 4 yr, respectively. Octreotide infusion was gradually weaned over 1 month. Continuous glucose monitoring after discontinuation of pump therapy showed normoglycemia. The first patient has now been treated with the lanreotide acetate for over 5 yr, and the second for 3 yr. Treatment is well-tolerated, and both the patients and their parents are satisfied with the transition from pump therapy to once-a-month injection and prefer it to pump therapy. Conclusion: Lanreotide acetate may be a safe and effective alternative to octreotide pump therapy in patients with CH, offering an improved quality of life. Longer follow-up of a larger patient group is needed.

Modern technologies in diabetes management - continuous glucose monitoring and insulin pump therapy

2021 ◽  
Vol 87 (1) ◽  
pp. 50-55
Author(s):  
E.Yu. Pyankova ◽  
◽  
L.A. Anshakova ◽  
I.A. Pyankov ◽  
S.V. Yegorova ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Diabetes Management ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
The Individual ◽  
Glucose Lowering Therapy

The problems of complications of diabetes mellitus cannot be solved without constant monitoring of blood glucose levels. The evolution of additional technologies for the determination of glucose in the blood of the last decades makes it possible to more accurately predict the risks of complications, both in the individual and in the patient population as a whole. The article provides an overview of the methods used in modern diabetology, facilitating control over the variability of blood glucose levels and helping in a more accurate selection of glucose-lowering therapy. All presented methods are currently working in real clinical practice in the Khabarovsk Krai

scholarly journals Glycemic Control and Hypoglycemia in Patients Treated with Insulin Pump Therapy: An Observational Study

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Guillermo Guzmán ◽  
Veline Martínez ◽  
Julián David Yara ◽  
Miguel Angel Mina ◽  
Juan Sebastian Solarte ◽  
...  
Keyword(s):  
Insulin Pump ◽  
Glycosylated Hemoglobin ◽  
Clinical Status ◽  
Life Quality ◽  
Glucose Monitoring ◽  
Severe Hypoglycemia ◽  
University Hospital ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Clinically Significant

Introduction. Diabetes mellitus (DM) is a highly prevalent disease worldwide. It has been associated with an important morbimortality due to its complications and sometimes as a result of adverse events related to treatment. Insulin pump therapy (IPT) is one of the options used to control this disease and reduces one of the most frequent complication associated with treatment: hypoglycemia, which has also a great impact on life quality and clinical status of patients. Materials and Methods. A descriptive and retrospective study was performed including patients treated and followed by the department of endocrinology from a high-complexity university hospital in Cali, Colombia, between 2012 and 2017. Patients were on IPT and continuous glucose monitoring (CGM): MiniMed Paradigm® Veo™ Insulin Pump (Medtronic®) and MiniMed 640G Insulin Pump-Enlite™ Sensor (Medtronic®). Presentation of hypoglycemia and variables associated with its development were evaluated. Results. 51 patients were included. The main indication for IPT initiation was the report of hypoglycemic episodes and inappropriate metabolic control. Initiation of IPT was related with a decrease in glycosylated hemoglobin (HbA1c) and also a decrease in severe hypoglycemic events and hospitalization due to hypoglycemia. The risk factors linked with clinically significant hypoglycemia were male gender, and standard deviation of glucose measures calculated by CGM. A diminished glomerular filtration rate (GFR) (<60 mL/min/1.73 m2) was correlated with higher risk of severe hypoglycemia. Conclusion. IPT with CGM is a useful strategy in the management of patients with DM; it is associated with a reduction of adverse hypoglycemic events and hospitalizations due to hypoglycemia.

scholarly journals Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update

2015 ◽  
pp. 1263 ◽  
Author(s):  
Andrea Tumminia ◽  
Laura Sciacca ◽  
Lucia Frittitta ◽  
Sebastiano Squatrito ◽  
Riccardo Vigneri ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Insulin Pump Therapy ◽  
Pump Therapy

Russian national guidelines on insulin pump therapy and continuous glucose monitoring for diabetes mellitus patients. DRAFT

2015 ◽  
Vol 61 (6) ◽  
pp. 55-78 ◽  
Author(s):  
Marina Vladimirovna Shestakova ◽  
Aleksandr Yuryevich Mayorov ◽  
Yury Ivanovich Philippov ◽  
Lyudmila Ibragimovna Ibragimova ◽  
Elena Vladimirovna Pekareva ◽  
...  
Keyword(s):  
Continuous Glucose Monitoring ◽  
Health Care Professionals ◽  
Clinical Guidelines ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Insulin Pump Therapy ◽  
Diagnostic Tools ◽  
High Tech ◽  
Pump Therapy ◽  
Diabetes Patients

Insulin pump therapy (continuous subcutaneous insulin infusion, CSII) and continuous glucose monitoring (CGM) are high-tech treatment and diagnostic tools for diabetes patients management which are actively used worldwide. CSII initiation and pump-users supervision became a part of routine clinical practice in Russia along with the CGM. Present project of clinical guidelines is based on international and domestic experience in CSII and CGM for diabetes treatment. Guidelines should ensure uniformity of CGM and CSII usage in Russia by health care professionals and diabetes patients and provide them an international experience to guarantee height performance of the technology. This article contains a preliminary version of the guidelines (draft) prepared for further expert’s discussion and review. The final version of the clinical guidelines will be sent to the Ministry of Health of the Russian Federation for approval.

Sign in / Sign up

Export Citation Format

Share Document